LTR Pharma initiates pivotal study of SPONTAN nasal spray in erectile dysfunction
LTR Pharma Limited (ASX:LTP), a company dedicated to advancing men’s health, has proudly announced the commencement of patient recruitment for a pivotal bioequivalence clinical study of its innovative nasal spray treatment for Erectile Dysfunction (ED), named SPONTAN. This landmark study aims to evaluate the relative bioavailability of Vardenafil via SPONTAN nasal spray compared to the […]